Reports Q1 revenue $46.9M, consensus $44.01M. “Our first quarter revenue exceeded our guidance range, and our base business, which excludes revenue from high-volume CleanCap(R) for commercial vaccine programs, grew more than $4 million compared to the fourth quarter of 2024, reflecting solid execution and momentum across the business,” said Trey Martin, CEO, Maravai LifeSciences (MRVI). “Our team remains committed to our return-to-growth strategy amid a dynamic and shifting macroeconomic environment. We believe our customer focus, our differentiated technologies and GMP services supporting clients from discovery through commercialization give us the best position to continue navigating the evolving landscape and drive long-term value for Maravai.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- MRVI Upcoming Earnings Report: What to Expect?
- MRVI Lawsuit Alert! Class Action Lawsuit Against Maravai Lifesciences Holdings
- Maravai Lifesciences price target lowered to $5 from $7 at Morgan Stanley
- Maravai LifeSciences Earnings Call: Growth Amid Challenges
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue